DTIL Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2018βFY2025
Precision Biosciences Inc had $34.3M of revenue in fiscal 2025, down 50.1% on the year before. Over five years, revenue changed +7.1% a year on average.
Last close Β· Oct 26, 2026
$6.41
β$0.31 (β4.61%) past year
Hi! I read Precision Biosciences Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β50.1%
No. Sales fell 50.1% last year.
Does it make a profit?
β133.4%
No. It lost money last year.
Does profit turn into cash?
β192.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA summarises the numbers
Precision Biosciences Inc had $34.3M of revenue in fiscal 2025, down 50.1% on the year before.
Over five years, revenue changed +7.1% a year on average.
Its operating margin was β152.2%, down 114.1Β pts: of every 100 in sales, about β152 is left after running the business.
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Loss periods are shown in red.
KIRA summarises the numbers
Precision Biosciences Inc lost $45.7M in fiscal 2025.
Net income
Net income
Diluted EPS
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
KIRA summarises the numbers
Free cash flow was β$65.9M in fiscal 2025, β192.4% of revenue.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
In the last 12 months, insiders bought $0.1M and sold $0.5M of shares on the open market.
Bought, 12 months
$0.1M
3 insiders
Sold, 12 months
$0.5M
4 insiders
Of sales under plans
100%
$0.5M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Stanley FrankelDirector | Bought | 1,000 | $6.00 | $0.0M | Form 4 |
| Sep 25, 2026 | Geno J GermanoDirector | Bought | 2,609 | $6.28 | $0.0M | Form 4 |
| Sep 25, 2026 | Melinda BrownDirector | Bought | 1,135 | $6.27 | $0.0M | Form 4 |
| Feb 18, 2026 | Dario ScimecaGeneral Counsel and Secretary | Sold plan | 4,925 | $3.84 | $0.0M | Form 4 |
| Feb 18, 2026 | Michael AmorosoPresident and CEO, Director | Sold plan | 20,559 | $3.84 | $0.1M | Form 4 |
| Feb 18, 2026 | J. Jefferson SmithChief Research Officer | Sold plan | 4,925 | $3.84 | $0.0M | Form 4 |
| Feb 18, 2026 | John Alexander KellyChief Financial Officer | Sold plan | 8,149 | $3.84 | $0.0M | Form 4 |
| Jan 22, 2026 | Michael AmorosoPresident and CEO, Director | Sold plan | 34,799 | $4.17 | $0.1M | Form 4 |
| Jan 21, 2026 | John Alexander KellyChief Financial Officer | Sold plan | 15,213 | $4.03 | $0.1M | Form 4 |
| Jan 21, 2026 | J. Jefferson SmithChief Research Officer | Sold plan | 10,200 | $4.03 | $0.0M | Form 4 |
| Jan 21, 2026 | Dario ScimecaGeneral Counsel and Secretary | Sold plan | 8,854 | $4.03 | $0.0M | Form 4 |
| Dec 16, 2025 | Geno J GermanoDirector | Bought | 3,000 | $4.72 | $0.0M | Form 4 |
| Dec 16, 2025 | Stanley FrankelDirector | Bought | 2,700 | $4.70 | $0.0M | Form 4 |
| Dec 15, 2025 | Melinda BrownDirector | Bought | 1,381 | $4.97 | $0.0M | Form 4 |
| Nov 3, 2025 | Dario ScimecaGeneral Counsel and Secretary | Sold plan | 665 | $6.49 | $0.0M | Form 4 |
| Nov 3, 2025 | John Alexander KellyChief Financial Officer | Sold plan | 1,303 | $6.49 | $0.0M | Form 4 |
| Nov 3, 2025 | Michael AmorosoPresident and CEO, Director | Sold plan | 3,409 | $6.49 | $0.0M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Precision Biosciences Inc can carry it.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $144M | $190M | $117M | $86.3M | $116M |
| Debt incl. finance leases | $2.5M | $22.2M | β | β | β |
| Debt / equity | 0.0x | 0.4x | β | β | β |
| Interest coverage | β298.3x | β56.1x | β19.6x | β14.7x | β36.7x |
| Current ratio | 4.5x | 3.3x | 2.7x | 6.3x | 13.3x |
| Quick ratio | 4.5x | 3.3x | 2.7x | 6.3x | 13.3x |
| Total assets | $211M | $238M | $160M | $136M | $154M |
| Total liabilities | $120M | $178M | $141M | $80.0M | $62.2M |
| Shareholders' equity | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M |
| Net debt (β = net cash) | β$141M | β$167M | β | β | β |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
Precision Biosciences Inc passes 1 of 7 financial health tests (Piotroski F-score).
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 1 / 7 | 4 / 7 | 2 / 8 | 2 / 7 | 4 / 7 | 1 / 7 |
| Accruals ratio | 4.1% | β11.7% | β11.2% | β10.9% | β29.3% | 11.5% | 44.3% | 13.8% |
| Altman Z'' | 0.91 | 1.20 | β7.94 | β1.44 | β3.42 | β8.14 | β8.23 | β7.20 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.9M | $1.1B | $24.3M | $116M | $25.1M | $48.7M | $68.7M | $34.3M |
| Research and development | $45.1M | $82.4M | $98.1M | $115M | $46.1M | $53.4M | $59.6M | $54.2M |
| Operating income | β$47.9M | β$87.2M | β$110M | β$39.4M | β$62.3M | β$43.7M | β$26.2M | β$52.1M |
| Interest expense | β | $0.2M | β | $0.1M | $1.1M | $2.2M | $1.8M | $1.4M |
| Pretax income | β | β | β | β | β | β | $7.2M | β$45.7M |
| Income tax | β | β | $0.0M | β | β | β | $0.0M | $0.0M |
| Net income | β$46.0M | β$92.9M | β$109M | β$30.6M | β$112M | β$61.3M | $7.2M | β$45.7M |
| Diluted EPS | β$2.92 | β$2.21 | β$2.09 | β$0.52 | β$38.10 | β$15.96 | $1.04 | β$3.56 |
| Diluted shares | 0.02B | 0.04B | 0.05B | 0.06B | 0.00B | 0.00B | 0.01B | 0.01B |
| Cash flow | ||||||||
| Cash from operations | β$51.7M | β$71.0M | β$87.4M | β$10.9M | β$45.8M | β$84.1M | β$58.4M | β$65.8M |
| Capital expenditure | $14.3M | $24.7M | $5.0M | $5.1M | $3.3M | $2.0M | $0.3M | $0.1M |
| Free cash flow | β$66.0M | β$95.7M | β$92.4M | β$15.9M | β$49.1M | β$86.1M | β$58.7M | β$65.9M |
| Depreciation and amortization | $2.4M | $5.3M | $8.8M | $9.0M | $7.8M | $6.8M | $3.4M | $1.5M |
| Stock-based compensation | $2.5M | $8.9M | $13.8M | $16.5M | $19.2M | $14.0M | $12.6M | $10.2M |
| Balance sheet | ||||||||
| Cash and short-term investments | $103M | $181M | $89.8M | $144M | $190M | $117M | $86.3M | $116M |
| Total debt | β | β | β | $2.5M | $22.2M | β | β | β |
| Current assets | $116M | $194M | $106M | $162M | $199M | $136M | $95.0M | $119M |
| Current liabilities | $14.1M | $26.9M | $42.8M | $36.0M | $59.7M | $50.0M | $15.0M | $8.9M |
| Property and equipment, net | $21.1M | $39.6M | $35.1M | $25.2M | $11.8M | $6.3M | $3.1M | $1.4M |
| Intangible assets | $1.5M | $1.4M | $1.4M | $2.0M | $0.7M | $0.4M | $0.6M | $1.2M |
| Total assets | $139M | $235M | $150M | $211M | $238M | $160M | $136M | $154M |
| Total liabilities | $98.6M | $96.9M | $106M | $120M | $178M | $141M | $80.0M | $62.2M |
| Preferred stock | β | β | β | β | β | β | $0.0M | $0.0M |
| Shareholders' equity | $40.0M | $138M | $44.4M | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M |
| Margins | ||||||||
| Operating margin | β440.2% | β8.1% | β452.2% | β34.1% | β248.3% | β89.8% | β38.1% | β152.2% |
| EBITDA margin | β418.6% | β7.7% | β416.1% | β26.3% | β217.2% | β75.8% | β33.1% | β147.9% |
| Net margin | β423.0% | β8.7% | β448.9% | β26.5% | β444.8% | β125.8% | 10.4% | β133.4% |
| FCF margin | β606.5% | β8.9% | β380.6% | β13.8% | β195.5% | β176.6% | β85.4% | β192.4% |
| Returns | ||||||||
| Return on capital employed | β38.5% | β41.9% | β102.3% | β22.4% | β34.9% | β39.8% | β21.5% | β35.8% |
| Return on equity | β115.2% | β104.2% | β119.3% | β45.1% | β147.3% | β154.7% | 19.0% | β61.5% |
| Return on assets | β33.2% | β49.7% | β56.6% | β16.9% | β49.7% | β30.8% | 4.8% | β31.4% |
| Return on tangible equity | β119.6% | β67.9% | β253.2% | β34.3% | β187.0% | β332.2% | 12.9% | β50.2% |
| Growth | ||||||||
| Revenue growth | β | 9,731.8% | β97.7% | 375.7% | β78.3% | 94.1% | 41.0% | β50.1% |
| Net income growth | β | β | β | β | β | β | β | β738.0% |
| EPS growth | β | β | β | β | β | β | β | β442.3% |
| Share count change | β | 166.2% | 23.9% | 12.8% | β95.0% | 31.1% | 79.2% | 86.3% |
| Financial health | ||||||||
| Debt / equity | β | β | β | 0.0x | 0.4x | β | β | β |
| Interest coverage | β | β479.1x | β | β298.3x | β56.1x | β19.6x | β14.7x | β36.7x |
| Current ratio | 8.2x | 7.2x | 2.5x | 4.5x | 3.3x | 2.7x | 6.3x | 13.3x |
| Quick ratio | 8.2x | 7.2x | 2.5x | 4.5x | 3.3x | 2.7x | 6.3x | 13.3x |
| Capital allocation | ||||||||
| Capex / revenue | 131.2% | 2.3% | 20.7% | 4.4% | 13.2% | 4.0% | 0.4% | 0.2% |
| Stock comp / revenue | 22.5% | 0.8% | 56.8% | 14.3% | 76.5% | 28.8% | 18.3% | 29.7% |
| Quality scores | ||||||||
| Piotroski F-score | β | 2.0 | 1.0 | 4.0 | 2.0 | 2.0 | 4.0 | 1.0 |
| Altman Z'' | 0.9 | 1.2 | β7.9 | β1.4 | β3.4 | β8.1 | β8.2 | β7.2 |
| Accruals ratio | 4.1% | β11.7% | β11.2% | β10.9% | β29.3% | 11.5% | 44.3% | 13.8% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001357874). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
